Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154234 | 1.00 | ROCK2 (0.51) | ROCK2HSP90AA1PTGS1PTGS2DGAT1 | |
| SCHEMBL6154056 | 0.89 | ROCK2 (0.66) | ROCK2PTGS1PTGS2DGAT1PARP10 | |
| SCHEMBL6153721 | 0.89 | ROCK2 (0.66) | ROCK2PTGS1PTGS2DGAT1PARP10 | |
| SCHEMBL6153723 | 0.89 | ROCK2 (0.66) | ROCK2PTGS1PTGS2DGAT1PARP10 | |
| SCHEMBL6156769 | 0.84 | ROCK2 (0.47) | ROCK2PTGS1PTGS2DGAT1PARP10 | |
| SCHEMBL6154351 | 0.84 | PTGS1 (0.52) | ROCK2HSP90AA1PTGS1PTGS2DGAT1 | |
| SCHEMBL6154356 | 0.84 | PTGS1 (0.52) | ROCK2HSP90AA1PTGS1PTGS2DGAT1 | |
| Cyanate SCHEMBL27865182 | 0.82 | PTGS1 (0.50) | ROCK2PTGS1PTGS2DGAT1PARP10 | |
| SCHEMBL6154534 | 0.82 | ACKR3 (0.48) | ROCK2PTGS1PTGS2FLT3 | |
| SCHEMBL4580326 | 0.78 | HSP90AA1 (0.55) | ROCK2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | ROCK2 2/4885HSP90AA1 1686/4885PTGS1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.